Clinical Trial Detail

NCT ID NCT01701986
Title Gemcitabine/Clofarabine/Busulfan and Allogeneic Transplantation for Aggressive Lymphomas
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements no
Sponsors M.D. Anderson Cancer Center
Indications

non-Hodgkin lymphoma

Hodgkin's lymphoma

Therapies

Tacrolimus

Rituximab

Filgrastim

Mycophenolate mofetil

anti-thymocyte globulin

Busulfan + Clofarabine + Gemcitabine

Age Groups: adult child

No variant requirements are available.